Abstract
PDE-5 inhibitors were originally studied in cardiovascular indications but were later developed and approved for on-demand treatment of erectile dysfunction (ED). A few years ago sildenafil was approved for the treatment of pulmonary hypertension, thus renewing interest in cardiovascular applications, and tadalafil became available in oncedaily formulations for erectile dysfunction management. Given the wide distribution of phosphodiesterase-5 throughout the body and its involvement in multiple functions, what can one expect in the future? To answer this we reviewed studies involving PDE-5 inhibitors that were published within the past three years and searched the US National Institutes of Health clinical trial registry for ongoing ones. PDE-5 inhibitors are being actively investigated in many disease states, with interest focusing mainly on urology and cardiovascular medicine. In urology erectile dysfunction is the primary target, followed by BPH-related lower urinary tract symptoms. As far as cardiovascular medicine is concerned, treatment of heart failure is the indication where PDE-5 inhibitors seem to be closer to clinical application but preclinical data also support a role in cardiac preconditioning.
Keywords: Phosphodiesterase-5 inhibitors, treatment, future, indications
Current Pharmaceutical Design
Title: Phosphodiesterase-5 Inhibitors: Future Perspectives
Volume: 15 Issue: 30
Author(s): Giannitsas Konstantinos and Perimenis Petros
Affiliation:
Keywords: Phosphodiesterase-5 inhibitors, treatment, future, indications
Abstract: PDE-5 inhibitors were originally studied in cardiovascular indications but were later developed and approved for on-demand treatment of erectile dysfunction (ED). A few years ago sildenafil was approved for the treatment of pulmonary hypertension, thus renewing interest in cardiovascular applications, and tadalafil became available in oncedaily formulations for erectile dysfunction management. Given the wide distribution of phosphodiesterase-5 throughout the body and its involvement in multiple functions, what can one expect in the future? To answer this we reviewed studies involving PDE-5 inhibitors that were published within the past three years and searched the US National Institutes of Health clinical trial registry for ongoing ones. PDE-5 inhibitors are being actively investigated in many disease states, with interest focusing mainly on urology and cardiovascular medicine. In urology erectile dysfunction is the primary target, followed by BPH-related lower urinary tract symptoms. As far as cardiovascular medicine is concerned, treatment of heart failure is the indication where PDE-5 inhibitors seem to be closer to clinical application but preclinical data also support a role in cardiac preconditioning.
Export Options
About this article
Cite this article as:
Konstantinos Giannitsas and Petros Perimenis, Phosphodiesterase-5 Inhibitors: Future Perspectives, Current Pharmaceutical Design 2009; 15 (30) . https://dx.doi.org/10.2174/138161209789206953
DOI https://dx.doi.org/10.2174/138161209789206953 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mediterranean Diet Rich in Olive Oil and Obesity, Metabolic Syndrome and Diabetes Mellitus
Current Pharmaceutical Design Withdrawn: Mesenchymal Stem Cell-derived Exosomes for Treatment of Ischemic Stroke
Current Stem Cell Research & Therapy Subject Index To Volume 2
Current Nutrition & Food Science Visfatin/PBEF and Atherosclerosis-Related Diseases
Current Vascular Pharmacology Clinical Assessment of Central Blood Pressure
Current Hypertension Reviews Hypoglycemic Agents in the Management of Type 2 Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery In vivo and in silico Investigation of Antidiabetic Activity of Fruit of Withania coagulans Dunal
Current Hypertension Reviews Rational Basis for Nutraceuticals in the Treatment of Glaucoma
Current Neuropharmacology Editorial [Genetic Pathways, Antenatal Care and Congenital Diaphragmatic Hernia: Are We There Yet? ]
Current Respiratory Medicine Reviews Development and Validation of a UPLC–MS/MS Method for the Simultaneous Determination of Telmisartan and Metformine HCl in Human Plasma
Current Analytical Chemistry Glycemic Variability, Oxidative Stress, and Impact on Complications Related to Type 2 Diabetes Mellitus
Current Diabetes Reviews Recent Patents on Ophthalmic Nanoformulations and Therapeutic Implications
Recent Patents on Drug Delivery & Formulation Tissue Plasminogen Activator (tPA) and Matrix Metalloproteinases in the Pathogenesis of Stroke: Therapeutic Strategies
CNS & Neurological Disorders - Drug Targets Biogenic Amines (BAs) in Meat Products, Regulatory Policies, and Detection Methods
Current Nutrition & Food Science Scleroderma Subsetting
Current Rheumatology Reviews Update on Medical and Surgical Management of Intracerebral Hemorrhage
Reviews on Recent Clinical Trials Biochemical Screening for in utero Drug Exposure
Drug Metabolism Letters Neural Control of Blood Pressure: Focusing on Capsaicin-Sensitive Sensory Nerves
Cardiovascular & Hematological Disorders-Drug Targets Losartan Chemistry and Its Effects via AT1 Mechanisms in the Kidney
Current Medicinal Chemistry Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery